We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mastectomy Slashes Cancer Risk in BRCA1/2 Women

By HospiMedica staff writers
Posted on 03 Mar 2004
A study has shown that bilateral prophylactic mastectomy reduces the risk of breast cancer by more than 90% in women with BRCA1 and BRCA2 mutations, and may be even more effective when performed concurrently with or following oophorectomy, or removal of the ovaries.

The findings were published in the February 23, 2004, issue of the Journal of Clinical Investigation. More...
A second study in the same issue showed that women undergoing removal of the ovaries can take short-term hormone replacement therapy (HRT) to combat the symptoms of menopause without fear of significantly increasing breast cancer risk.

Among the 105 women who had bilateral prophylactic mastectomy, breast cancer was diagnosed in two (1.9%), compared to 184 of the 378 (48.7%) who did not undergo the procedure. Mastectomy reduced the risk of breast cancer by about 95% among women with prior or concurrent prophylactic oophorectomy, and by 90% among women with intact ovaries. Although removal of the breasts and the ovaries does not completely prevent breast and ovarian cancer, the researchers strongly recommended that all women with the BRCA mutations undergo oophorectomy at the completion of child bearing.

"Undergoing prophylactic mastectomy is a very personal decision. Women who choose to have their breasts removed in addition to their ovaries should know that prophylactic mastectomy is an option that really works, and makes taking HRT after oopherectomy even safer,” said senior author Dr. Barbara Weber, professor of medicine and genetics at the University of Pennsylvania (Philadelphia, USA).




Related Links:
University of Pennsylvania

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Medical Examination & Procedure Light
Vega 80
New
Gas Analyzer
GE SAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.